
CAS Name: 3-[2-(Diethylamino)ethyl]-3-phenyl-2,6-piperidinedione
Additional Names: 2-(2-diethylaminoethyl)-2-phenylglutarimide; a-phenyl-a-(diethylaminoethyl)glutarimide; 3-phenyl-3-(b-diethyla...
Literature References: Anticholinergic. Prepn: Tagmann et al., Helv. Chim. Acta 35, 1235 (1952); 37, 185 (1954); Hoffmann, Tagmann, US 2664424 (1953 to Ciba).
CAS Name: [3(S)-endo]-8-(2-[1,1'-Biphenyl]-4-yl-2-oxoethyl)-3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-azoniabicyclo[3.2.1]octane bromide
Additional Names: 3a-hydroxy-8-(p-phenylphenacyl)-1...
Literature References: Anticholinergic. Prepn: U. Teotino, D. Della Bella, GB 1026640; eidem, US 3356682 (1966, 1967 both to Whitefin Holding); Teotino et al., Chim. Ther. 3, 453 (1968). Human pharmacology: Azzollini et al., Curr. Ther. Res. 12, 734 (1970). Clinical studies: Alberto et al., Minerva Med. 62, 852 (1971).
CAS Name: endo-8,8-Dimethyl-3-[(1-oxo-2-propylpentyl)oxy]-8-azoniabicyclo[3.2.1]octane bromide
Additional Names: 3a-hydroxy-8-methyl-1aH,5aH-tropanium bromide 2-propylvalerate; 8-methyltropiniu...
Literature References: Anticholinergic. Prepn: Weiner, Gordon, US 2962499 (1960 to Endo Labs.). Metabolism: Shindo et al., Chem. Pharm. Bull. 19, 513 (1971). Clinical trial in ulcer: J. H. Bowers et al., J. Clin. Pharmacol. 18, 365 (1978).
CAS Name: a-Cyclohexyl-a-phenyl-1-piperidinepropanol hydrochloride
Additional Names: 3-(1-piperidyl)-1-cyclohexyl-1-phenyl-1-propanol hydrochloride; 1-phenyl-1-cyclohexyl-3-piperidyl-1-propanol...
Literature References: Anticholinergic. Synthesis: Denton et al., J. Am. Chem. Soc. 71, 2053 (1949); Adamson, Wilkinson, US 2682543 (1954 to Burroughs Wellcome); Denton, US 2716121 (1955 to Am. Cyanamid). Resolution into isomers: Adamson, Duffin, GB 750156 (1956 to Wellcome Found.).
CAS Name: [1,1'-Bicyclohexyl]-1-carboxylic acid 2-(diethylamino)ethyl ester
Additional Names: b-diethylaminoethyl 1-cyclohexylcyclohexanecarboxylate; bis(cyclohexyl)carboxylic acid diethylamino...
Literature References: Anticholinergic; binds to muscarinic M1 receptors. Prepn: C. H. Tilford et al., J. Am. Chem. Soc. 69, 2903 (1947); M. G. Van Campen, C. H. Tilford, US 2474796 (1949 to Merrell). Receptor binding study: H. Kilbinger, A. Stein, Br. J. Pharmacol. 94, 1270 (1988). Capillary GC determn in plasma: B. J. Walker et al., J. Chromatogr. 416, 150 (1987). Clinical trial in functional abdominal pain: M. G. Grillage et al., Br. J. Clin. Pract. 44, 176 (1990).
Trademarks: Exhirud (Sanofi Winthrop); Hirudex (Cooper)
Literature References: Anticoagulant protein extracted from the salivary glands of the medicinal leech, Hirudo medicinalis Linn. Hirudin is a single chain polypeptide containing 65 amino acids; mol wt approximately 7000 daltons. Several isoforms have been identified. A specific inhibitor of thrombin, q.v., hirudin does not require the presence of other coagulation factors. Isoln: J. B. Haycraft, Arch. Exp. Pathol. Pharmakol. 18, 209 (1884). Initial characterization: F. Markwardt, Naturwissenschaften 42, 537 (1955). Improved isoln: P. Walsmann, F. Markwardt, Thromb. Res. 40, 563 (1985). Amino acid sequence: T. E. Petersen et al. in Protides of the Biological Fluids vol. 23, H. Peeters, Ed. (Pergamon Press, London, 1976) pp 145-149. Antithrombin activity: F. Markwardt, Methods Enzymol. 19, 924 (1970). Pharmacokinetics in humans: F. Markwardt et al., Thromb. Haemostasis 52, 160 (1984). Chromogenic assay in plasma: U. Griessbach et al., Thromb. Res. 37, 347 (1985). Series of articles on development, pharmacology, and therapeutic potential of natural and recombinant hirudins: Semin. Thromb. Hemostasis 15, 261-333 (1989). Review of pharmacology and therapeutic potential: P. H. Johnson, Annu. Rev. Med. 45, 165-177 (1994); of therapeutic use in myocardial infarction: U. Zeymer, K.-L. Neuhaus, Drug Saf. 12, 234-239 (1995).
CAS Name: 2-Hydroxy-1,2,3-propanetricarboxylic acid trisodium salt
Additional Names: trisodium citrate
Trademarks: Citrosodine (GSK); Cystemme (Abbott); Urisal (Sanofi-Synthelabo)
Percent...
Literature References: Anticoagulant use in blood transfusion: R. Weil, J. Am. Med. Assoc. 64, 425 (1915); cf. ibid. 250, 1901 (1983). Toxicity study: C. M. Gruber, Jr., W. A. Halbeisen, J. Pharmacol. Exp. Ther. 94, 65 (1948). Clinical evaluation of antacid efficacy: C. P. Gibbs et al., Anesthesiology 57, 44 (1982); of effects on athletic performance: V. Oöpik et al., Br. J. Sports Med. 37, 485 (2003).
CAS Name: N-[(4-Methoxyphenyl)methyl]-N',N''-dimethylguanidine
Additional Names: 1-(p-methoxybenzyl)-2,3-dimethylguanidine
Percent Composition: C 63.74%, H 8.27%, N 20.27%, O 7.72%
Literature References: Antidysrhythmic, antifibrillatory deriv of guanidine, q.v. Prepn of the sulfate: R. A. Maxwell, E. Walton, DE 2030693 corresp to US 3949089 (1971, 1976 both to Burroughs Wellcome). Antidysrhythmic effects and tissue concentration: K. B. Touw et al., Pharmacologist 19, 268 (1977); K. B. Touw, Diss. Abstr. B 39, 5340 (1979). Pharmacokinetics by radioimmunoassay: J. W. A. Findlay et al., Pharmacologist 21, 337 (1979). Pharmacological study: W. B. Wastila et al., J. Pharm. Pharmacol. 33, 594 (1981).
CAS Name: 3-Chloro-4-(2,5-dioxo-3-phenyl-1-pyrrolidinyl)benzenesulfonamide
Additional Names: 3-chloro-4-(phenylsuccinimido)benzenesulfonamide; 1-(a-phenylsuccinimido)-2-chloro-4-sulfamoylbenzen...
Literature References: Anti-epileptic agent. Prepn: R. W. Pfirrmann, BE 752109; idem, US 3789056 (1970, 1974 both to Geistlich). Pharmacology: Arzneim.-Forsch. 27, 1942 (1977). HPLC determn in biological materials: F. Mikes et al., ibid. 29, 1583 (1979).
CAS Name: 1-[(2,6-Difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide
Additional Names: 1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamideTrademarks: Inovelon (Eisai)
Percent Composit...
Literature References: Antiepileptic triazole derivative which decreases firing by neurons at sodium channels. Prepn: R. Meier, EP 199262; eidem, US 4789680 (1986, 1988 both to Ciba-Geigy). HPLC determn in human plasma: L. A. Brunner, M. L. Powell, Biomed. Chromatogr. 6, 278 (1992). Clinical pharmacokinetics: W. K. Cheung et al., Pharm. Res. 12, 1878 (1995); and tolerability: J.-M. Cardot et al., Biopharm. Drug Dispos. 19, 259 (1998). Clinical study in epilepsy: S. Palhagen et al., Epilepsy Res. 43, 115 (2001). Review of clinical experience: K. K. Jain et al., Exp. Opin. Invest. Drugs 9, 829-840 (2000).
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
